🗓️ Today is World Leukemia Day! 🧫 Blood cancer impacts the production and development of blood cells. These types of cancer originate in the bone marrow where blood is produced, and can interfere with the function of blood cells, leading to various complications. Leukemia is the 13th most common cancer in the world. Over 437,000 people are diagnosed with leukemia each year, that’s over 1000 people every day. However, the non-specific signs and symptoms make it difficult to spot. There are over 300,000 deaths caused by leukemia worldwide. Join us to support Acute Leukemia Advocates Network, #CLLANAdvocatesNetwork, and CML Advocates Network during #WorldLeukemiaDay! Discover more about AML 👉 https://bit.ly/4aGoTsK and ALL 👉 https://bit.ly/4bDUIDy #BeLeukemiaAware #WLD24 #WorldLeukemiaDay #leukemia #BloodCancerAwarenessMonth
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
After raising awareness on the importance of measuring blood pressure, it’s now time ❤️ for Act 2 focused on adherence to hypertension treatment: #BeTheCaptainOfYourLife! 50% of patients discontinue their hypertension and/or dyslipidemia treatments after 6 months. Are you ready to help us 🗣️ spread the word on the importance of 💊treatment adherence? Follow us on Facebook and Instagram. Find out more about hypertension, screening, and prevention 👉 https://lnkd.in/ewwc_HR5 #TakeYourMedicine #BecauseIsayso #adherence #hypertension #BloodPressure #awareness #BloodPressureControl #TakeControl #HypertensionAwareness
-
The 2024 #ESCCongress is now over! We were pleased to share with the global cardiology community the latest in cardiovascular science and up‑to‑date education. As part of our Ambition 2030 strategy, at Servier, we are committed to fighting ❤️ cardiovascular diseases and will continue to invest in innovative solutions. Our objective? To help patients and HCPs improve the management of these diseases! Learn more about our commitments 👉 https://lnkd.in/eJrTQQRN #CardiovascularMedicine #patient #Servier2030
-
-
-
-
-
+1
-
-
This month we’re supporting #ChildhoodCancerAwarenessMonth & #BloodCancerAwarenessMonth 💪 📈 Annually, over 1.24 million new cases of blood cancer are diagnosed, accounting for 6% of all new cancer diagnoses. Among them, Acute Lymphoblastic Leukemia represents approximately 25% of all pediatric cancer diagnoses. At Servier, we aim to be a focused and innovative player in oncology. Each year, we invest over 70% of our R&D budget in oncology, particularly to develop treatments for rare cancers. To learn more about our commitment 👉 https://swll.to/KTflT #ChildhoodCancer #BloodCancer
-
For years, we've been committed to raising awareness about ❤️ cardiovascular diseases, and particularly the importance of treatment adherence. 👋 Attending the #ESCCongress? Come and meet us to discover our new awareness campaigns – #BecauseIsayso #Actnowonangina #EveryBeatMatters – at our booth No. D590 Learn more about our long-term commitment to fighting cardiovascular diseases 👉 https://bit.ly/3qUooJP #hypertension #angina #HeartFailure #cardiology European Society of Cardiology
-
✨ Significant progress in medicine has made it possible to treat and control illnesses that would previously have been fatal. Yet, one third of the world’s population cannot access these essential treatments. Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world. Through our first iconic CSR project, at Servier, we seek to contribute to achieving the World Health Organization’s goal to 🏥 increase the survival rate of children with cancer globally to at least 60% by 2030. The success of the project requires progress in three areas—improving access to existing treatments, investing in R&D, and supporting patients, their family and health care professionals. Read more on this challenge 👉 https://bit.ly/3AjT5g8 #csr #AccessToMedicines #oncology #WeAreServier #MovedByYou
-
-
👋 We’re attending the 2024 #ESCCongress. This annual event brings together leading experts in cardiology to share the latest research and advances in the field. This year, we’re offering a dedicated booth experience! HeartTour is a unique journey to showcase our expertise, from diagnostics to our portfolio and the innovative solutions beyond the pill. We look forward to meeting you at our booth – No. D590 – and at the 3 symposiums held by Servier: 📌 “Leveraging real-world evidence in hypertension management: from data to patient-centric care” on August 31 - 10:00–10:45 am (CEST) 📌 “Chronic ischemic syndrome management in 2024: are we ready for the (r)evolution?” on August 31 - 12:30–1:30 pm (CEST) 📌 “Dyslipidemia management: a cornerstone in cardiovascular multimorbid patients’ care” on September 1 - 10:00–10:45 am (CEST) Learn more about our long-term commitment to fighting cardiovascular diseases 👉 https://bit.ly/3qUooJP #hypertension #angina #HeartFailure #cardiology European Society of Cardiology
-
🚀 Did you miss our first Golden Ticket campaign in France for start-ups to integrate Spartners by Servier and BioLabs France? 😀 The winning start-up gets close support from our experienced teams, and free access to the incubator's shared facilities and numerous programs and services. In this first edition held in July, we had 🏆 4 finalists in this Saclay 2024 campaign and they were all great at pitching their start-ups!👍 🧬 One Biosciences 🧬 kyron.bio 🧬 RA Ventures Ltd (https://lnkd.in/ekptjCPj) 🧬 Exosome Analytics 👏 Congratulations to Kyron.bio, which is the winner! Well done Emilia McLaughlin!🤩 🧬 If you're a biotech specializing in healthcare, stay tuned! We’ll be back very soon before the end of 2024! Learn more about Spartners by Servier and BioLabs 👉https://lnkd.in/eBa9FKzG #biotech #startup #incubator #innovation
-
🌍 At Servier, we have reduced Scope 1 and 2 greenhouse gas emissions by 11% compared to 2021-2022. 💪 In 2022-2023, 57% of our Group’s intercontinental shipments were transported by sea. Our commitment to environmental sustainability drives us to minimize our carbon footprint and create a greener future. Together, let’s make a positive impact for a healthier planet! ♻️🌎 Learn more about Servier 👉 https://servier.com/en/ #Climate #WeAreServier #MovedByYou #Environment #ServierInFigures
-
👋 Have you seen it? ⁉️ Organized by HealthTech For Care, the HealthTech Innovation Days (HTID®) will take place on September 17 - 18. Don’t miss this opportunity to connect, collaborate, and contribute to the evolution of healthcare. 👉 Pre-register now https://lnkd.in/e7ZP-ZCv See you there! Let's shape the future of healthcare together. #HTID6 #innovation #biotech #Medtech
#SAVETHEDATE 🗓️ Organized by HealthTech For Care, the HealthTech Innovation Days (HTID®) will take place on September 17 - 18. This event aims to foster new industrial partnerships and investments in biotechs to accelerate the development of and accessibility to new treatments for patients. That is why we have actively 💪 supported #HTID since its very first edition. Don’t miss this opportunity to connect, collaborate, and contribute to the evolution of healthcare. 👉 Pre-register now https://lnkd.in/e7ZP-ZCv See you there! Let's shape the future of healthcare together. #HTID6 #innovation #biotech #Medtech
-